Entry-level electric saloon is on display in UK dealerships; RHD deliveries scheduled for mid-2019

Tesla has opened the order books for European customers of its Model 3 saloon, revealing previously-unconfirmed pricing and range details. 

UK cars aren't expected until the middle of next year when right-hand drive production commences, but prices published in Spain, Sweden, Netherlands and France suggest the entry-level EV will be available from £50,000, falling to £46,500 after taking into consideration the UK government incentive for zero-emission vehicles.

The Model 3 has also been shown in UK dealerships for the first time, with demonstration models on display in the company's London Park Royal and Manchester Stockport dealerships. 

The Model 3 is capable of covering 338 miles on a single charge, according to new WLTP testing methods. This figure applies to the four-wheel drive Long Range variant, which available with 50kWh or 75kWh batteries.

*Tesla Model 3 review​*

Currently, only the standard and performance Long Range options are available in Europe, with subsequent cheaper variants expected to be available from around £30,000 in the UK. That will pitch the Model 3 against the likes of the Audi A4, BMW 3 Series, Jaguar XE and Mercedes-Benz C-Class in terms of pricing and size.

Model 3 production hit 5000 cars a week in the last week of June 2018, just meeting Tesla's self-set output deadline for that number of cars to be made in a week by the end of the second quarter of 2018.

It required the construction of a temporary 'tent' outside the firm's California factory, to hold another production line and increase output.

It's estimated that around 500,000 orders have been received for the Model 3, which costs from $35,000 (£26,500) in the US before incentives. 

The 50kWh model hits 0-60mph in 5.6sec and has a top speed of 130mph. The Long Range model can do 0-60mph in 5.1sec and has a 140mph top speed, costing from $44,000 in the US. 

The Model 3 is more than 400kg lighter than the Model S, so it could be quicker than the Performance version of that car.

Model 3 owners will not get free access to the Tesla Supercharger high-speed charging system, with the company planning to charge for electricity as demand grows and it requires more investment to build up the network of chargers.

However, if Tesla hits its planned production of 500,000 cars a year - something it has faced an uphill struggle to achieve until the recent 5000-car milestone - analysts predict that it will outsell BMW, Mercedes-Benz and Lexus in the US.

*Prospective Tesla Model 3 owners tell us why they're buying one*

Tesla launched its Semi lorry and a new Roadster last year, following an injection of $1 billion (around £800 million) worth of investment into the company - something Musk has previously said would help the company meet high demand for the Model 3.

Tesla has raised capital to help production and ease the financial risk associated with the production run. This has led to a rise in its share price and has been further boosted by reports of its future model plans, including the Model Y compact SUV, according to New York financiers.

However, some analysts still question Tesla's ability to ramp up production to meet its demand. The brand is yet to make a profit, although the latest reports suggest it could do so later this year.

*Read our Tesla Model X road test*

*Read more - Tesla's Gigafactory in numbers* Reported by Autocar 2 hours ago.

PALO ALTO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- DeepMap, leading provider of high-definition (HD) mapping and localization technology for autonomous vehicles, today announced licensing deals with Swedish trucking company Einride and San Francisco-based new mobility platform provider Ridecell. Both companies are integrating DeepMap’s software into autonomous fleets.

James Wu, CEO and Co-Founder of DeepMap, said: “The visionary teams at Einride and Ridecell are pushing the industry forward and we are delighted to work closely with them. We are particularly excited about helping our self-driving partners accelerate their fleet deployments at multiple locations and for different vehicle models.”Einride develops electric-powered autonomous vehicles for road freight transport. The company has two vehicle models: the T-pod, designed to transport pallets, and the T-log, designed to transport logs. The vehicles are autonomous and have no driver’s cab but can be remote-controlled by a human operator. An Einride T-pod is in use by logistics company DB Schenker on a public commercial route in Sweden. Einride will deploy its first truck using DeepMap’s mapping software in 2019.Ridecell provides a new mobility cloud platform for carsharing, ridesharing, and autonomous ridehailing services. In 2017, Ridecell acquired Auro Robotics, which is now Ridecell’s self-driving car division. DeepMap’s software will be integrated into Auro’s self-driving vehicle technology.Robert Falck, Founder and CEO of Einride, commented: “Einride is on a mission to decarbonize road freight transportation. By removing the driver’s cab, we get a lighter vehicle, allowing us to change from diesel to electricity. Self-driving technology is a key enabler for a sustainable transformation of the transportation industry and DeepMap’s technology is a key enabler for self-driving.”Srinivas Reddy Aellala, Principal Product, Auro, Autonomous Driving Division of Ridecell, said: “DeepMap provides best-in-class mapping software features, helping Auro reduce its AV deployment time and effort at complex and remote sites. We look forward to working with DeepMap as we continue to enhance our autonomous offering.”*About DeepMap*
DeepMap is focused on solving the mapping and localization challenge for autonomous vehicles. DeepMap delivers the capabilities necessary for self-driving cars to navigate in the complex and unpredictable real world by addressing three important elements: precise high-definition mapping, ultra-accurate real-time localization, and the serving infrastructure to support massive global scaling. The technology allows HD mapping by autonomous vehicles and for autonomous vehicles. The company was founded in 2016 and is headquartered in Palo Alto, Calif., with offices in Beijing, China. For more information, see www.deepmap.ai.Contact: media@deepmap.ai Reported by GlobeNewswire 2 hours ago.

Reported by Telegraph.co.uk 2 hours ago.

DGAP-News: KROMI Logistik AG / Key word(s): AGM/EGM

05.12.2018 / 18:04
The issuer is solely responsible for the content of this announcement.
--------------------

*KROMI holds successful 2018 AGM*

*Hamburg, December 5, 2018 - KROMI Logistik AG, a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations, successfully held its 2018 Annual General Meeting today, Wednesday. The presence of attended share capital amounted to 88.62%, and all agenda items were approved.*

As part of the AGM, the Managing Board reported in detail on KROMI's operative and strategic development during the 2017/18 fiscal year, noting that while the current market environment for KROMI is competitive, it is also attractive inasmuch as it offers a number of potentials for the future. In fiscal 2017/18, this situation led the Managing and Supervisory boards to initiate a further development of the business model, in order to ensure that the services it offers form an exact fit with individual customer requirements in the future. With the technological and organisational experience it has gathered over almost 20 years of market leadership, the KROMI Managing Board regards the company as well positioned to benefit from such potentials with the business model it has further developed. KROMI's new self-perception as a technology company has also been consistently implemented in a new brand profile. In accordance with its "Tooling - One Step Ahead" claim, the declared objective is to always stay one step ahead in the expertise areas of Tools, Logistics, Data and Technology.

In addition, Mr. Ulrich Bellgardt, Chairman of the Supervisory Board since 1 January 2018, and Mr. Bernd Paulini, Spokesman of the Management Board since the beginning of 2018 and Chairman of the Management Board (CEO) with effect from 1 November 2018, presented themselves in their new roles at the Annual General Meeting. After having held senior positions at KROMI over the past 18 years, Mr. Uwe Pfeiffer also bid his official farewell. He supported KROMI's development as both a member of its Supervisory Board and, since 2007, as its Chief Financial Officer. Following some very constructive discussions, the Supervisory Board and Mr. Pfeiffer jointly agreed that Mr. Pfeiffer would already leave KROMI as of December 31, 2018, in order to be able to devote himself to new tasks within the near future. Mr. Paulini will assume his tasks on an acting basis until Mr. Pfeiffer's successor Mr. Christian Auth takes up his position on April 1, 2019.

The AGM approved all of the management's proposed agenda items with very large majorities. In particular, the AGM granted discharge to the Managing and Supervisory boards in relation to the fiscal year elapsed.

*Company profile: *
KROMI, Hamburg, is a manufacturer-independent expert in optimising tool availability and tool deployment in machining operations. As a reliable and transparent partner to industry, KROMI combines machining technology, data management and streamlined logistics processes to form compelling all-round solutions. Thanks to networked dispensers in customers' production areas in combination with digital inventory controlling, KROMI ensures the optimal utilisation and availability of the requisite working resources at the right time and in the right place. The activities of KROMI aim to always offer maximum value for customers' machining operations in its core markets of Europe and Brazil. This entails analysing processes on the customer side in detail and identifying opportunities and potential improvements, in order to optimally integrate tool supplies with all requisite services. KROMI currently has sites in Germany, Slovakia, the Czech Republic, Spain and Brazil. KROMI is also active in five further European countries.

Visit us on the Internet at:* *www.kromi.de

Investor relations contact:
cometis AG
Claudius Krause
Tel.: +49 (0)611-205855-28
Fax: +49 (0)611-205855-66
Email: krause@cometis.de
--------------------

05.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: KROMI Logistik AG
Tarpenring 11
22419 Hamburg
Germany
Phone: 040/537151-0
Fax: 040/537151-99
E-mail: info@kromi.de
Internet: www.kromi.de
ISIN: DE000A0KFUJ5
WKN: A0KFUJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart
 
End of News DGAP News Service Reported by EQS Group 2 hours ago.

Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "The Global Ethanolamines Market" report has been added to *ResearchAndMarkets.com's* offering.

This report presents a strategic analysis of the global ethanolamines market and a forecast for its development in the medium term. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc.
According to recently conducted research about the global ethanolamines market, as an overall, it is projected to reach approximately 2,459 thousand tons by the end of 2023, increasing at a CAGR of around 3% per year in the period 2017-2023.

The report focuses on both product and regional breakdown, offering a larger perspective on the market dynamics. Although ethanolamines are predominantly used as chemical absorbents for gas treatment, the analysis considers the application of ethanolamines across various industries.

In particular, the second largest share of ethanolamines consumption is as absorbents for gas treatment, which accounted for around 27% of the total in volume terms. Meanwhile, the chemical's application for gas separation has been growing with the highest rate of about 3.89% per year.

Regionally, the largest global ethanolamines market was North America, which accounted for about 30% of the total in volume terms. In comparison, Africa was the smallest global ethanolamines market during the analyzed period and is expected to remain such in the medium term.

Diethanolamine is one of the key raw materials in the production of glyphosate, which contributes to the high quality of the herbicide by enhancing its effect in agrochemical applications. Furthermore, as glyphosate is the largest consumed variety of herbicides, its growing demand in recent years has considerably fueled the global ethanolamines market.

Furthermore, ethanolamines' application in cosmetics and personal care products is differently regulated by the authorities in different regions. Although the European Commission banned the use of diethanolamine in cosmetics, in the USA it can be found in products such as soaps, hair conditioners, hair dyes, shampoos and many more.

Most applications of ethanolamines can be considered mature. MEA consumption for triazines has a promising outlook, on a contrary to its consumption in wood preservatives, which has declined slightly in the last few years.

Geographically, owing to the strong need for cement, gas treatment, pharmaceuticals, agricultural and personal care products, consumption for ethanolamines in recent years was highest in the North American region. Europe has retracted the use of glyphosate, resulting in dramatically less consumption of glyphosate and diethanolamine.*Key Topics Covered*

*1. Introduction*
1.1. Report description
1.2. Research methodology

*2. Executive summary*

*3. Characteristics of ethanolamines *

*4. State of the global demographics and economy*
4.1. Characteristics of the global demographics in 2013-2017
4.2. Characteristics of the global economy in 2013-2017
4.3. Forecast for the development of the global economy in the medium term

*5. Overview and analysis of the global ethanolamines market*
5.1. Volume and dynamics of the global ethanolamines market in 2013-2017 and forecast for 2018-2023
5.2. Structure of the global ethanolamines market by main regions in 2013-2017 and forecast for 2018-2023
5.3. Structure of the ethanolamines market in Africa by countries in 2013-2017 and forecast for 2018-2023
5.4. Structure of the ethanolamines market in Asia and Pacific by countries in 2013-2017 and forecast for 2018-2023
5.5. Structure of the ethanolamines market in the CIS countries by countries in 2013-2017 and forecast for 2018-2023
5.6. Structure of the ethanolamines market in Europe by countries in 2013-2017 and forecast for 2018-2023
5.7. Structure of the ethanolamines market in the Middle East by countries in 2013-2017 and forecast for 2018-2023
5.8. Structure of the ethanolamines market in North America by countries in 2013-2017 and forecast for 2018-2023
5.9. Structure of the ethanolamines market in North East Asia by countries in 2013-2017 and forecast for 2018-2023
5.10. Structure of the ethanolamines market in South and Central America by countries in 2013-2017 and forecast for 2018-2023
5.11. Structure of the global ethanolamines market by application/main product groups in 2013-2017 and forecast for its development in 2018-2023
5.12. Key recent trends on the global ethanolamines market
5.13. Key drivers and restraints for the market development in the medium term

*6. Overview and analysis of the global production of ethanolamines*
6.1. Volume, distribution and dynamics of the installed capacities for the global production of ethanolamines broken down by regions in 2013-2017 and forecast for their development in 2018-2023
6.2. Volume and dynamics of the average annual utilization rates used for the production of ethanolamines globally, broken down by regions, in 2013-2017 and forecast for their development in 2018-2023
6.3. Volume and dynamics of the global production of ethanolamines in 2013-2017 and forecast for 2018-2023
6.4. Structure of the global production of ethanolamines in 2013-2017 by main regions and forecast for 2018-2023
6.5. Structure of the ethanolamines production in Africa by countries in 2013-2017 and forecast for 2018-2023
6.6. Structure of the ethanolamines production in Asia and Pacific by countries in 2013-2017 and forecast for 2018-2023
6.7. Structure of the ethanolamines production in the CIS countries by countries in 2013-2017 and forecast for 2018-2023
6.8. Structure of the ethanolamines production in Europe by countries in 2013-2017 and forecast for 2018-2023
6.9. Structure of the ethanolamines production in the Middle East by countries in 2013-2017 and forecast for 2018-2023
6.10. Structure of the ethanolamines production in North America by countries in 2013-2017 and forecast for 2018-2023
6.11. Structure of the ethanolamines production in North East Asia by countries in 2013-2017 and forecast for 2018-2023
6.12. Structure of the ethanolamines production in South and Central America by countries in 2013-2017 and forecast for 2018-2023
6.13. Characteristics of the main producers of ethanolamines globally along with their exact installed capacities and used production techniques

*7. Characteristics and analysis of the global prices of ethanolamines*
7.1. Value chain analysis
7.2. Structure of price formation
7.3. Characteristics of the global prices of ethanolamines in 2013-2017 and forecast for 2018-2023
7.4. Characteristics of the regional prices of ethanolamines in 2013-2017 and forecast for 2018-2023

*8. Overview and analysis of the global imports of ethanolamines*
8.1. Volume, value and dynamics of the global imports of ethanolamines in 2013-2017
8.2. Structure of the global imports of ethanolamines by main regions in 2013-2017
8.3. Average prices of the ethanolamines, imported globally in 2013-2017

*9. Overview and analysis of the global exports of ethanolamines*
9.1. Volume, value and dynamics of the global exports of ethanolamines in 2013-2017
9.2. Structure of the global exports of ethanolamines by main regions in 2013-2017
9.3. Average prices of the global exports of ethanolamines in 2013-2017

*10. Balance between supply and demand on the global ethanolamines market*
10.1. Balance between supply and demand on the global ethanolamines market in 2013-2017 and forecast for 2018-2023
10.2. Balance between supply and demand on the global ethanolamines market by main regions in 2013-2017 and forecast for 2018-2023

* Companies Featured*· Akzo Nobel
· Amines & Plasticizers
· Anhui Huaihua Chemical
· Asian Petroprod & Exports
· Basf
· Beifang Chemical
· Dow Chemical
· Equistar Chemicals
· Fushun Jiahua Polyurethane Co. Ltd.
· Gspcl/K. Tharkoral & Co.
· Hubei Xianlin Cc
· Huntsman International
· Indust. Derivadas Etileno
· Ineos Oxide
· Jiangsu Sailboat Petrochemical
· Jiangsu Yinyan
· Jilin Zhongxin Chemical Group
· Kazanorgsyntez
· Kpx Green Chemical
· Liaoning North Chemical
· Lotte Sanjiang
· Mitsui Chemicals
· Nippon Shokubai
· Oriental Union Chemical
· Oxiteno
· Petrochina Jilin Pc
· Petronas Chemicals Derivatives
· Sadara Chemical Company
· Sasol
· Saudi Kayan
· Shanghai Fujia Fine Chemical
· Shazand Petrochemical
· Sinopec Maoming Pc
· Sinopec Shanghai Gaoqiao Co.
· Sintez Oka
· Thai Ethanolamines
· Yixing Zhoutie Dyestuff

For more information about this report visit https://www.researchandmarkets.com/research/wtfl8b/the_global?w=12

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Chemical Auxiliary Agents Reported by GlobeNewswire 2 hours ago.

Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to *ResearchAndMarkets.com's* offering.

Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Autism Spectrum Disorder (ASD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Autism Spectrum Disorder (ASD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

*Geography Covered*

· The United States
· EU5 (Germany, France, Italy, Spain and the United Kingdom)
· Japan

*Study Period:* 2016-2027

*Autism Spectrum Disorder (ASD) - Disease Understanding and Treatment Algorithm*

Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is said to be a developmental disorder because symptoms generally appear in the first two years of life. ASD refers to a group of neurodevelopmental conditions defined by impairment in three areas: social interaction, communication or use of verbal and non-verbal language, and a stereotyped, restricted or repetitive pattern of behavior, interests and activities.

Autism Spectrum Disorder (ASD) is used to be called as Pervasive Developmental Disorder (PDD). PDD included five types or categories: Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder, Rett's Syndrome, and pervasive developmental Disorder-Not Otherwise Specified (PDD-NOS).

The Autism Spectrum Disorder (ASD) market report gives the thorough understanding of the ASD by including details such as disease definition, classification, Etiology, Pathophysiology, Signs and Symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Autism Spectrum Disorder (ASD) in the US, Europe, and Japan.

*Autism Spectrum Disorder Epidemiology*

The Autism Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD), Gender Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD) and Subtype-Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD)] scenario of ASD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per the study conducted by Guifeng Xu et al., titled as Prevalence of Autism Spectrum Disorder among US Children and Adolescents, 2014-2016, the estimated prevalence for Autism Spectrum Disorder was 2.47% among US children and adolescents in 2014-2016, with no statistically significant increase over the 3 years. The observed prevalence was higher than estimates in previous years from the ADDM, although differences in study design and participant characteristics may partly explain the prevalence differences.

The total 7MM prevalent cases of Autism Spectrum Disorder in 2016 were 6,545,050 out of which the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 57% of the total prevalent cases. The EU5 countries accounted for 1,715,717 cases as a whole in 2016. Japan had 1,094,393 cases in 2016, which accounted for approximately 17% of the total 7MM prevalent cases of Autism Spectrum Disorder. The total prevalent cases of ASD in 7MM is calculated by adding the prevalent cases of the individual country.

According to this research, total prevalent population of Autism Spectrum Disorder (ASD) in the 7 major markets is estimated approximately 6,545,050 cases in 2016 and it is expected to be change during the forecasted period (2016-2027).

This research estimates that the prevalent population of Autism Spectrum Disorder (ASD) in 7MM is expected to change for the study period 2016-2027.

This research estimates a higher prevalence of Autism Spectrum Disorder (ASD) in the United States with 3,734,939 cases in 2016.

*Autism Spectrum Disorder Drug Chapters*

This segment of the Autism Spectrum Disorder (ASD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic market for Autism Spectrum Disorder (ASD) is being dependent on the two FDA approved products including Johnson's Risperdal and Otsuka's Abilify and one EMA approved Neurim's Slenyto. Other off-label therapies are also being used to improve the signs and symptoms of the disease. Drugs commonly prescribed to Autism Spectrum Disorder (ASD) patients include antipsychotics, antidepressants, selective-serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS depressants and others.

Key players such as Roche, Neurochlore/Servier, Optinose, Yamo Pharmaceuticals, Curemark, etc. are developing emerging therapies for the treatment of patients with Autism Spectrum Disorder (ASD). Expected launch of emerging therapies such as Balovaptan (Roche), Bumetanide (Neurochlore/Servier), OPN-300 (Optinose), L1-79 (Yamo Pharmaceuticals), CM-AT (Curemark), are expected to increase the market size of ASD in upcoming years.

*Autism Spectrum Disorder (ASD) Market Outlook*

The Autism Spectrum Disorder (ASD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Autism Spectrum Disorder (ASD) in 7MM was found to be USD 2510.2 million in 2016, and is expected to increase from 2016-2027.

The United States accounts for the largest Autism Spectrum Disorder (ASD) market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

*Autism Spectrum Disorder (ASD) Drugs Uptake*

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

*Autism Spectrum Disorder (ASD) Report Insights*

· Patient Population
· Therapeutic Approaches
· Pipeline Analysis
· Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies

*Autism Spectrum Disorder (ASD) Report Key Strengths*

· 10 Years Forecast
· 7MM Coverage
· Epidemiology Segmentation
· Key Cross Competition
· Highly Analyzed Market
· Drugs Uptake

*ASD Report Assessment*

· Current Treatment Practices
· Unmet Needs
· Pipeline Product Profiles
· Market Attractiveness
· Market Drivers and Barriers

*Key Benefits*

· This report will help to develop Business Strategies by understanding the trends shaping and driving Autism Spectrum Disorder (ASD) market
· Organize sales and marketing efforts by identifying the best opportunities for Autism Spectrum Disorder (ASD) market
· To understand the future market competition in the Autism Spectrum Disorder (ASD) market.

*Companies Mentioned *· Roche
· Neurochlore/Servier
· Curemark
· Yamo Pharmaceuticals
· Johnson and Johnson
· Otsuka Pharmaceutical
· Neurim Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r3xnhv/autism_spectrum?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 2 hours ago.

Agreement between North American Vendor and Australian Distributor accelerate reach and access of market-leading email security solution

Montreal, Canada, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Vircom is proud to announce the launch of a unique regional distribution partnership with SecureSoft, a premier distributor of cybersecurity products in the Asia-Pacific region, for its modusCloud and modusGate email security solutions, allowing SecureSoft to offer on-premise and cloud email protection, advanced threat protection, email continuity, email encryption, email archiving and more to partners throughout the region.
“The team at Vircom is glad to see the reach and quality of our customer base expanding tremendously with the offering of both our modusCloud and modusGate solutions,” says Mike Petsalis, CEO of Vircom. “With the addition of SecureSoft, a long-tenured distributor in the Asia-Pacific region that is exceeding 15% year-over-year growth, we look forward to seeing customers in the region get more access to a top-tier service and support offering with faster turnaround and response times than ever before.”

Interested in achieving global reach without diluting customer service experience or support, Vircom anticipates that, as per the agreement, SecureSoft will deliver outstanding front-line support to partners in the region while they are always able to escalate severe or emergency issues to Vircom’s 24/7 global support team.

“We love both the pedigree and the future that Vircom has to offer its customers,” adds Jacques Tesson, CEO and Founder of SecureSoft. “Our partners have found compelling value in our offering, which bundles management tools, email filtering and endpoint protection in such a way that allows partners to address most of their security threats through one, easy-to-work-with distributor.”

With threats proliferating through all channels, and the means to address them often sparing in global markets, partnerships that assist organizations of all sizes in serving more SMBs, MSPs and the cohort of organizations that make up the majority of global business are crucial. “We know the threats from bad actors, whether through email, malware or other risks, have gone global. Vendors, distributors and all manner of service providers need to respond to them globally,” adds Mr. Petsalis.

“With partners like SecureSoft in the Asia Pacific and others in Europe, the Middle East, Africa and throughout the Americas, we look forward to delivering solutions that can empower organizations to address and manage the risks they face, not only reducing their costs and enabling them to be better at their own work, but also collectively reducing the challenges we face in securing our information technology infrastructures.”

  

*About Vircom*

Vircom has, for more than two decades, been providing cutting-edge solutions that keep IT Teams and Service Providers serene and effective. Vircom’s latest offering, modusCloud, gives SMBs and MSPs some of the most powerful cloud email security on the market, featuring filtering driven by machine learning, Advanced Threat Protection, Data Loss Prevention (DLP), Email Encryption, and Email Archiving. With over 3000 customers and more than 3 million mailboxes protected, Vircom is helping organizations of all sizes meet their security needs as they transition to Office 365 and other cloud systems, along with providing unique integrations that make it easier for MSPs to manage their customers.

*About SecureSoft*

SecureSoft Distribution Pty Ltd (SecureSoft) brings powerful intuitive cybersecurity solutions to new markets in APAC. Located in Sydney Australia, SecureSoft has been providing a safer online community since 2008, protecting thousands of businesses and tens of thousands of endpoints. SecureSoft offers state of the art cybersecurity solutions and services from world-leading companies that represent latest generation technologies covering advanced cloud and on-prem web filtering and email protection solutions, email encryption and archiving, anti-virus and anti-malware endpoint software and management consoles. SecureSoft remains dedicated to providing value and opportunity to all our partners and stakeholders.

 

*Press Contacts*

Robert Ravensbergen

Marketing Manager at Vircom

5148451666 ext. 310

robert.ravensbergen@vircom.com

 

Steve Cronan

National Business Manager at SecureSoft

+61 2 8459 2039

steve@securesoft.com.au

CONTACT: Robert Ravensbergen
Vircom
5148451666 ext310
robert.ravensbergen@vircom.com

Steve Cronan
SecureSoft
+61 2 8459 2039
steve@securesoft.com.au Reported by GlobeNewswire 2 hours ago.

Organized crime is active across Europe, with groups generating over €100 million in revenue every year. Here's a list of some of the most prominent organizations. Reported by Deutsche Welle 2 hours ago.

4 primary blockchain corporations have fashioned a “Blockchain for Europe” Affiliation, in keeping with a press liberate Dec. five. The affiliation seeks to advertise the figuring out and proactive legislation of blockchain and different allotted ledger (DLT) applied sciences around the continent. The 4 player corporations are Ripple, the NEM Basis, Emurgo – which helps … Reported by The News Articles 2 hours ago.

In the forecast report for 2019, the Investment Research Team at UBS, expect the greenback to retain its strength in the near term, but they think the dollar is likely to depreciate over time as policy normalization gets underway in Europe. 

*Key Quotes: *

“The USD remains overvalued thanks to marked positive short-term interest rate differentials as the Federal Reserve continues to raise interest rates. This state of affairs, along with the dispute over Italy’s budget, is likely  to prompt further near-term gains for the USD relative to the EUR.”

“Looking further ahead, we expect the Fed to near the end of its rate-hiking cycle in 2019, while the European Central Bank (ECB) will only be starting to normalize interest rates, which will cause the differentials to shrink and the dollar’s advantage to recede, in our view.”

“The support for US growth from fiscal stimulus will also wane next year, and the US twin fiscal and current account deficits are likely to start to weigh on the dollar.”

“We forecast EURUSD at 1.15 and 1.20 over six and 12 months. A key risk to our view is the US launching a large infrastructure program, which could boost growth and inflation. The dollar could also remain stronger relative to the euro if US-China trade frictions intensify in 2019, Eurozone data slows, or the ECB appoints a dovish successor to current president Mario Draghi.”
  Reported by FXstreet.com 2 hours ago.

International Banker recently held its annual Banking Awards to acknowledge the top banking institutions and individuals in Western and Eastern Europe. Handelsbanken’s CEO Anders Bouvin was honored with the prestigious Banking CEO of the Year Western Europe 2018 Award.

LONDON (PRWEB) December 05, 2018

International Banker offers a global view of banking and finance. Each year through the Banking Awards, it recognizes the leading banking institutions and individuals that have set the bar for industry excellence. The 2018 Banking Awards acknowledge the organizations and individuals within the banking and financial industries in Western and Eastern Europe that drive global economic commerce, create capital and opportunities for economic growth within their regions, set the benchmarks for technological advancement and customer service, while maintaining high levels of regulatory compliance and corporate governance. The standout institutions working within retail, commercial, investment and private banking are recognized with these awards. In addition, special awards are given to outstanding CEOs in each region.

Honored with the award for Banking CEO of the Year Western Europe 2018 to acknowledge and celebrate his leadership in banking, Anders Bouvin, CEO of Sweden’s Handelsbanken, has achieved a prominent position on the International Banker Western and Eastern Europe Awards 2018 list.

Handelsbanken—headquartered in Stockholm, Sweden, but with more than 800 branches in its six home markets—makes it very clear that customer satisfaction is its guiding principle. Handelsbanken has a long history. Established in 1871, it has undergone many changes since its inception, yet it has kept hold of the fundamental importance of maintaining a local presence, as other banks have closed branches and replaced them with automation. For both its personal and corporate customers, Handelsbanken’s promise to meet their, “requirements for financial services—with the highest possible level of satisfaction” remains as true today as it was a century ago.

At the head of it all is President and Group CEO Anders Bouvin, who is determined to actualize the bank’s business strategy. “We aim to be more profitable than our competitors—in terms of RoE—by having more satisfied customers and lower costs.” This strategy is definitely working, with return on equity rising to 13.8 percent in the January–June 2018 period from 12.6 percent in the same period of last year. 2017 marked the 46th consecutive year that the bank produced higher profitability than the average of its competitors.

The judges for the prestigious Banking CEO of the Year Western Europe 2018 Award noted that under Anders Bouvin’s leadership, Handelsbanken has embarked on a digitalization strategy that focuses on the bank’s key strengths and differentiators within the industry. The strategy incorporates and builds on the uniquely decentralized model of the bank by placing a strong emphasis on increasing the quality of personal meetings and the level of advice and service at the branch level. CEO Anders Bouvin has demonstrated his commitment to expansion within all the markets the bank operates. Handelsbanken has increased its number of customer investment-advice meetings held by its Swedish branches by 64 percent year-on-year; this has been accomplished with branch staff who have no sales activity targets or personal sales incentives. But Mr. Bouvin is determined not to force the expansion of the bank. A branch is opened only when a suitable branch manager has been found to head it up. He views that expenditure to increase customer satisfaction as not a cost but an investment, and the responses to customer-satisfaction surveys support this approach. Anders Bouvin’s plan to focus on the fundamentals of increasing customer satisfaction and cost efficiency is a clearly defined and sustainable long-term strategy for Handelsbanken’s growth.

The judges were also impressed by Handelsbanken’s and Anders Bouvin’s personal commitment to the Global Child Forum and the United Nation’s Agenda 2030’s Sustainable Development Goals—such as sustainable cities and communities, and gender equality.

For more information, please visit https://internationalbanker.com/banking/interview-with-mr-anders-bouvin-president-and-group-ceo-handelsbanken/

About International Banker: International Banker is the flagship brand of Finance Publishing. Finance Publishing is one of the world’s leading sources of authoritative analysis on finance, international banking and world affairs. It delivers information with excellence through a wide range of accessible formats, from websites, newsletters and magazines, to conferences. For more information, please visit http://internationalbanker.com Reported by PRWeb 1 hour ago.

DGAP-News: Biom'up / Key word(s): Financing

05.12.2018 / 19:15
The issuer is solely responsible for the content of this announcement.
--------------------

*Biom'up launches a private placement financing of a minimum of EUR7 million*
 

· *Capital increase without preferential subscription rights to the benefit of certain categories of investors*
· *Delivery of the new 8,700 sqm production facility expected in 2021*
· *Financial information update*

*Saint-Priest, France, December 5, 2018, 7:15 p.m. (C.E.T.) *- Biom'up (the "*Company*"), a specialist in surgical hemostasis, announces the launch of a capital increase by the issuance of new shares without preferential subscription rights for the benefit of a category of beneficiaries (the "*Offer*"). Biom'up wishes to raise a minimum of EUR7 million.*Objectives*

The proceeds of the Offering are mainly intended to provide the Company with additional resources to accelerate its development. Accordingly, the net proceeds from the funds raised within the framework of the Offering, i.e. a minimum of EUR7 million, will allow the Company to finance, in the following order of priority and in equal proportions:

· the continuation and ramp up of clinical development for HEMOBLAST^TM Bellows in abdominoplasty surgery, knee surgery and spinal surgery.
 
· continuing expenditures for the construction of the new production plant near the existing site (the Company now estimates this new plant could supply up to 500,000 units of HEMOBLAST Bellows by the end of 2021 v. 2020 initially).

To achieve its 2022 target of a 15% market share in the United States and the main European countries, the Company will need additional financing.
 
· ongoing efforts to deploy the sales force in the United States and Europe, ramping up efforts devoted to marketing and training practitioners and the Company's ordinary operating activities.*Structure of the Offering*

The New Shares (the "*New Shares*") will be offered in connection with a capital increase, entailing the cancellation of preferential subscription rights for the benefit of categories of persons set by the 5^th resolution of the extraordinary general meeting of the shareholders of June 5, 2018, in compliance with article L. 225-138 of the French commercial code (the "*Capital Increase*").

These categories include notably one or more companies or French or foreign investment funds who customarily invest, or have invested more than EUR1 million during the 36 months preceding the date of the issue in question, in the life sciences or health technology sector.

Financière Arbevel, acting on behalf of the UCITS and investment mandates that it manages, shareholders of the Company holding 6.68% of the share capital (5.92% on a fully diluted basis), and Athyrium Capital Management L.P., fund manager of the shareholder investment fund of the Company holding 1.43% of the share capital (3.37% on a fully diluted basis) have undertaken to invest respectively EUR2 million and EUR5 million in the Offer. These subscription commitments cover the entirety of the minimum amount of the Capital Increase.

The New Shares whose admission to trading on the regulated market of Euronext Paris will be requested shall be ordinary shares of the Company, subscribed for and paid up in full, and reserved and allocated to investors meeting the above characteristics. These shares are subject to an offering consisting of (i) a "book-building" process in the European Economic Area (the "EEA") under the derogation provided for by Article 3.2 of the 2003/71/EC Directive of the European Parliament and Council dated November 4, 2003 (as amended), and (ii) a private placement outside the EEA in accordance with the rules of each country concerned, and in particular outside of the United States by virtue of Regulation S of the U.S. Securities Act of 1933, as amended (the "*Securities Act*") and in the United States by virtue of an exemption from the registration requirements of the Securities Act to Qualified Institutional Buyers (QIBS) as defined by Article144A of the U.S. Securities Act.

In accordance with articles 211-3 and 212-5 of the general Regulation of the AMF, neither the Offer nor the admission of the New Shares to trading on the regulated market of Euronext Paris shall be subject to a prospectus having been granted clearance by the AMF.

The New Shares may be listed only after their issuance at the end of the settlement-delivery of New Shares scheduled for December 10, 2018.

Placement of the New Shares will be assured by Bryan Garnier & Co acting as placement agent under the terms of an underwriting agreement to be concluded with the Company. This underwriting agreement does not constitute a performance guarantee (garantie de bonne fin) within the meaning of Article L. 225-145 of the French commercial code. The Company will grant, under the terms of this agreement, an abstention commitment (whereby it will not proceed with any issue or grant any promise of sale of shares or securities giving access to the capital of the Company), for a period of 90 days expiring after the date of settlement-delivery of the New Shares in the absence of a prior written agreement of the Placement Agent or application of the usual exceptions.

The Company's historic shareholders with a stake in the capital before the IPO of October 13, 2017 and Kreos Capital V (UK) Ltd, a holder of share warrants, remain subject to a lock-up commitment for the Company's shares for those securities giving access to the capital they hold or will come to hold until December 31, 2018.*Preferential subscription rights*

The issue of New Shares will be made with the cancellation of preferential subscription rights reserved for categories of beneficiaries in compliance with the provisions of article L.225-135 of the French Commercial Code.

In this framework, at the General Meeting of June 5, 2018 (5^th resolution) the Company's shareholders decided to cancel their preferential subscription rights for the benefit of investors meeting the above characteristics.*Subscription price*

The final conditions of the Offer, including the subscription price and the impact of the issue of New Shares on the percentage of capital held and the situation of the shareholder will be announced as soon as possible by the issuance of a press release.*Indicative timetable for the Offer*

December 5, 2018 (post-closing) Decision of the Board of Directors deciding on the launch of the Offer and its main procedures.

Press release announcing the launch of the Capital Increase
 
December 6, 2018 Decision of the Board of Directors setting the issue price of the New Shares and the final procedures of the Offer (or the chief executive officer when this authority has been delegated to the latter) (before the opening of trading on the stock market)

Execution of the Underwriting Agreement

Press release announcing the Offer price and the final amount of the Capital Increase (before the opening of trading)
 
December 7, 2018 Publication by Euronext of the notice of admission of the New Shares to trading
December 10, 2018 Settlement-Delivery and admission to trading of the New Shares on Euronext Paris.

 

*Update of information concerning the company*

The Company was created in 2005 with the objective of designing and producing implantable, resorbable biomaterials and medical devices derived from biopolymers like collagen. The Group has also developed a new generation of hemostasis products composed of patent-protected biopolymers.

The development strategy is now focused on (i) HEMOBLAST Bellows, a hemostatic powder (acting to control minimal to moderate bleeding during surgical procedures) equipped with a bellows applicator and (ii) HEMOSNOW^TM, a hemostatic dry powder enabling mechanical or activation for minimal bleeding during surgical procedures. The HEMOBLAST product range can be used in many surgical fields only with the applicator or in conjunction with a 10 cm cannula in most open surgical procedures or with the assistance of a 35 cm laparoscopic cannula in laparoscopy for example.

HEMOBLAST Bellows obtained CE marking in December 2016. In the United States, following completion of the Premarket Approval (PMA), in December 2017, the Group received FDA marketing approval in the United States for HEMOBLAST Bellows, 7 months in advance of the original plan.

The product's official commercial launch in Europe and the United States took place in the summer of 2018, with the first sales recorded in July 2018.

Thanks to the productivity improvement, the doubling of the number of shifts, and the expansion of the capacity of production of HEMOBLAST Bellows subsequent to the capacity freed up by the discontinuation of legacy products, the production site in Saint-Priest is now able to produce 4,000 units of HEMOBLAST Bellows per month. This capacity is anticipated to increase to 7,000 units per month by the first semester of 2019. Delivery of a new 8,700 sqm production facility is now expected in 2021 v. 2020 initially; the Company anticipating this new site to produce up to 500,000 units of HEMOBLAST Bellows per year by end of 2021. In order to achieve the 15% market shares in the United States of America and main European countries in 2022, the Company will need additional financing.*Net working capital*

Since its creation, the Company has financed its growth by strengthening its equity through successive capital increases, and by obtaining public grants for innovation, the reimbursement of research tax credit receivables and through bank borrowings through bond issues.

The cash balance was at EUR33.1 million at September 30, 2018 and EUR28.8 million at October 31, 2018. The Company has completed a specific review of its liquidity risk and considers that it is unable to honor the terms for future payments (based on a qualified situation of deficiency as of the September 2019). The working capital deficiency would attain a maximum amount of EUR6.8 million within 12 months, i.e. end of December 2019. The Company however considers the net proceeds of the Offer will be sufficient to meet its obligations and operating cash flow needs during the twelve months. This Offering is the Company's preferred solution for obtaining positive net working capital for the next twelve months.

The Company will continue to have significant financing requirements in the future. The Company will consider different sources of financing (equity, debt or other non-dilutive solutions) to guarantee the Company's continuity as a going concern after December 2019. Until the end of March 2019, and subject to fulfillment of certain conditions, the Company has an option to raise an additional EUR10 million from Athyrium in connection with the March 2018 bond issue.*Profit-sharing plans adopted before the Company's initial public offering*

After reviewing the situation of the share price and its consequences for profit-sharing plans set up pursuant to the delegations of authority granted by the shareholders' general meetings of February 19, 2015 and July 17, 2015 (for BSPCE warrants) and June 21 2016 (for stock options), and in light of notably the exercise price of the instruments in question, i.e. 236,413 BSPCE warrants exercisable at a price of EUR16.80 for two new shares and 52,579 stock options exercisable under the same conditions, and the shares limited liquidity, on October 29, 2018 the Board decided, on the recommendations of the nomination and compensation committee, to propose to each beneficiary employed by the Group on October 29, 2018 to substitute a fixed amount of EUR4.20 per dilutive instruments (or EUR2.10 per underlying share) or a total amount of EUR418,198.20, in exchange for waiving their rights to said instruments, it being specified that the beneficiaries are corporate officers who waived theirs rights to these instruments without compensation.

The offer of substitution was opened to beneficiaries until November 30, 2018, the date on which the beneficiaries had responded favorably. On that basis, the summary of potentially dilutive instruments on the Prospectus date is as follows:
 

*Nature of the dilutive instruments* *Number of instruments* *Potential new shares*
BSPCE founders' warrants (Bons de souscription de parts de créateur d'entreprise)
Stocks options 418,705 418,705
Warrants 217,320 492,320 *
Restricted stock units 406,360 406,360
*Total* 1,042,385 1,317,385 **

 

* Increase to a maximum of 612,320 new shares, taking into account the 120,000 new shares that could be issued from exercising the BSA warrants attached to the bond subscribed by Athyrium in respect of the second tranche of EUR10 million, not yet issued on this date.

** Increase to a maximum of 1,437,385 new shares, taking into account the 120,000 new shares that could be issued from exercising the BSA warrants attached to the bond subscribed by Athyrium Capital Management L.P. in respect of the second tranche of EUR10 million, not yet issued on the date of the Prospectus.*Biom'up USA, Inc.*

Biom'up USA, Inc. is the US subsidiary of the Company responsible for the distribution of the Group's products in its priority market, the United States. On September 18, 2018 Biom'up USA Inc., appointed Mr. William Spotnitz, also the Group's Chief Medical Officer, as Chief Executive Officer, in replacement of Mr. Etienne Binant, also the Company's Chief Executive Officer (directeur général), now occupying the offices of Chairman of Biom'up USA, Inc. In light of the progress and success of the US subsidiary under Mr. Etienne Binant's management between March 2015 and September 2018, this subsidiary granted him a bonus of a net amount in US dollars equal to EUR490,095.*Availability of the registration document and the interim financial report*

Detailed information about Biom'up, notably relating to its business, results, outlook and the corresponding risk factors is provided in the Company's registration document for 2017, filed with the AMF on May 28, 2018 (No. R.18-043), and in the interim financial report for the six-month period ended June 30, 2018 which may be consulted along with other regulated information and all press releases of the Company at the Biom'up website (www.biomup.com).*Contacts*

*Biom'up*
Chief Financial Officer
Jean-Yves Quentel
investisseurs@biomup.com
+33 4 86 57 36 10 *MC Services AG *
International Investor and Public Relations
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252-22 *Alize RP*
Investor Relations
Caroline Carmagnol
biomup@alizerp.com
+33 6 64 18 99 59*About HEMOBLAST*

HEMOBLAST Bellows is a hemostatic product to control bleeding in a broad range of surgical procedures, such as cardiac surgery, general surgery, and orthopedic surgery, etc. Biom'up conducted a successful clinical trial in the United States with 412 patients admitted to cardio-thoracic, abdominal or orthopedic (lower limb) surgeries which met all of its primary and secondary endpoints. Given the compelling preliminary results (93 % effectiveness at 6 minutes, compared with 74 % for the control arm), the Independent Data Monitoring Committee (IDMC) unanimously recommended to stop the study after an interim analysis of the data, which allowed the company to accelerate the submission of its filing for premarket approval (PMA) to regulatory authorities in June 2017.

After obtaining expedited FDA approval for HEMOBLAST Bellows in December 2017, 7 months ahead of original plan, Biom'up's efforts are focused on industrial and commercial activities and the recruitment of sales and marketing teams in the U.S. to prepare the planned commercial roll-out of our lead product in the United States.

On July 12, 2018, Biom'up obtained CE Marking for its HEMOBLAST Bellows Laparoscopic Applicator designed to deliver the HEMOBLAST Bellows powder in minimally-invasive procedures. This has opened the way for the Company in a new market segment representing approximately 500,000 surgeries per year in Europe. In addition, on July 2, 2018 the Company filed a PMA supplement to obtain approval for HEMOBLAST Bellows for all laparoscopic surgical procedures in the United States.*About Biom'up*

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom'up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life.

Since its creation, Biom'up has benefited from the support of prominent European investors such as Bpifrance, Innobio, Gimv, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the company's managers, who have invested EUR2 million in equity. Biom'up successfully completed its IPO on Euronext Paris, raising EUR42.5 million in October 2017. This has been followed by a EUR16 million capital increase in February 2018 and a EUR25 million bond financing agreement with Athyrium Opportunities III Acquisition LP, a US fund specializing in innovative companies in the healthcare sector, in March 2018.*Warning*

This document and the information contained herein do not constitute an offer to sell or purchase, or the solicitation of an offer to sell or purchase, securities of Company.

No disclosures or other any information relating to the issue of Company's shares may be distributed to the public in any jurisdiction where a registration or approval is required. No formalities have been or will be undertaken in any jurisdiction outside France where such measures would be required. The offering or subscription of the shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility for any violation of such restrictions by any person.

This document does not constitute and shall not be construed as constituting a public offer or offer to purchase nor a solicitation to the public in connection with a public offering. The distribution of this document may in certain countries be governed by specific regulations. Any persons in possession of this document should seek advice on and comply with any local restrictions.

This announcement is an advertisement and does not constitute a prospectus within the meaning of Prospectus Directive (as defined below), to the extent such Directive has been transposed in each of the Member States of the European Economic Area.

With regard to Member States of the European Economic Area (including France) (the "*Member States*") that have transposed the Prospectus Directive, no action has been taken or will be taken to make an offer to the public of the securities requiring a publication of a prospectus in one of the Member States. As a result, the securities of the Company may not and will not be offered in any Member State other than France, except in accordance with the exemptions set forth in Article 3 of the Prospectus Directive.

For the purposes of this provision, an "offer to the public" in relation to the new or existing shares of the Company in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as modified, if applicable, by the Member State. "Prospectus Directive" herein refers to the Directive 2003/71/EC (as amended, including by Directive 2010/73/EC), and any relevant transposition measure in the Member State.

This document may not be distributed, directly or indirectly in the United States of America. This document is neither an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States of America or any other jurisdiction where such offer may be restricted. The securities of the Company may not be offered or sold in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended ("*US Securities Act*"). The securities of the Company have not been and will not be registered under the U.S. Securities Act and the Company does not intend to make a public offer of its securities in the United States of America.

In the United Kingdom, distribution of this document (referring to any form of communications) is subject to restrictions provided for by article 21 (restrictions relating to "financial promotion" of the Financial Services and Markets Act 2000 (" *FSMA*"). This document is distributed to, and is directed only at persons who are (i) investment professionals under Article 19(5) of the FSMA (Financial Promotion Order) 2005 (the "Order") as amended, (ii) persons falling within Article 49(2)(a) to (d) of the Order and (iii) any person to which this document may be legally transmitted (all persons mentioned in (i), (ii) and (iii) together being referred to as "Relevant Persons". This document must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Any investment to which this document relates may be proposed to or engaged in the United Kingdom only with Relevant Persons. By receiving this document, you must notify the Company that you are among the categories of persons mentioned above.
--------------------

05.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Biom'up
8, allée Irène Joliot Curie
69800 Saint-Priest
France
Phone: +33 (0)4 86 57 36 10
Fax: +33 (0)4 37 69 00 84
E-mail: contact@biomup.com
Internet: www.biomup.com
ISIN: FR0013284080
WKN: A2H5VA
Listed: Regulated Unofficial Market in Berlin; London, Paris
 
End of News DGAP News Service Reported by EQS Group 1 hour ago.

EBENSBURG, Pa., Dec. 05, 2018 (GLOBE NEWSWIRE) -- viLogics, a trusted IT solutions provider with more than 20 years’ experience in information technology and data center services, has completed a rigorous examination of its data security processes to achieve compliance with the Health Insurance Portability and Accountability Act (HIPAA) and the System and Organization Controls 2 Type 2 standards.The demanding third-party examinations were administered by the professional IT assurance and compliance staff at 360 Advanced, a respected national Qualified Security Assessor, HITRUST CSF Assessor and Certified Public Accountant firm based in St. Petersburg, FL.The SOC 2 report attests to the effectiveness of the data management controls a company has in place that relate to security, availability, processing integrity, confidentiality and privacy.“We had actually been operating in accordance with the SOC 2 compliance standards for more than two years, and formalizing that compliance by achieving these third-party audits clearly demonstrates our dedication to data security on all levels of our operations,” commented* Shawn Long, CEO*.“Our clients are now demanding these assessments so they can outsource their data management processes and focus on their core services. It is no longer an option, and having these designations are essential as we execute our strategy to grow in medical and other business sectors.”

*ABOUT VILOGICS*viLogics delivers highly effective IT solutions that provide exceptional value, innovation, assurance, and integrity. The firm’s technology solutions promise forward thinking and innovation that leverages the strengths of its clients’ people, processes and technologies to meet and exceed their objectives.

*ABOUT 360 ADVANCED*A trusted Cybersecurity Compliance firm with proficiencies in SOC reporting, 360 Advanced assists service providers in more than 40 U.S. states, Europe, South and Central America and the Pacific Rim as their independent IT assurance and compliance assessor. Services provided by 360 Advanced include HITRUST CSF, GDPR, SOC 1, SOC 2, SOC for Cybersecurity, PCI DSS, HIPAA Security/HITECH, Microsoft Vendor Policy and other security and compliance services.For an initial consultation, please contact eratcliffe@360advanced.com Reported by GlobeNewswire 1 hour ago.

· *In European markets, the two standouts, for opposites, were Italy that outperformed due to 'positive' progress on a budget agreement with the EU while for the UK, Brexit continued to create just about enough angst in government concerns to send the FTSE lower that was also weighed by some pretty shocking services data. *
· *In France, the CAC 40 continues to be troubled by political challenges and public unrest, despite Macron caving in under the pressures and backing down on the gas tax. *

European markets are still feeling the heat following a switch up in sentient surrounding global growth prospects and global trade relations. At the same time, the political environment is as uncertain as ever, on both mainland Europe and Britain. While there may have been some clarity found today over legalities over Article 50, it still does not bode well for UK politics and the future of the Conservative party.

*Closing percentage changes for European indexes*

· UK FTSE 100 -1.44%
· German DAX -1.19%
· French CAC -1.36%
· Italy MIB -0.1%
· Spain IBEX -0.55%

Germany stocks were in the doldrums again on Wednesday with the Technology, Insurance and Software sectors weighing on Frankfurt's major index.  The DAX dropped 1.19% with the worst of the index coming from Wirecard AG which dropped 2.67% or by 3.700 points to trade at 134.850 by the end of the session. Infineon Technologies AG NA O.N.fell  2.39% or 0.450 points to end at 18.355 and Fresenius Medical Care KGAA ST dropped 2.18% or 1.600 points to 71.720. Helping to support the index was Heidelbergcement AG O.N. which added 0.46% or 0.260 points to trade at 57.360 and Bayer AG NA also rose 0.43% or by 0.28 points to finish the day at 65.61. RWE AG ST O.N. added 0.41% or 0.080 points to 19.390 by the close.

*Brexit draws **most** attention*

The main news came from London on Wednesday. UK multinationals shares were weighed by a strong pound while the FTSE 100 was down 1.1% at 6,943.23 as Brexit angst continues to linger despite some positives have come of recent legal advice which could mean that Brexit may not happen at all. As for shares, housebuilders rallied, with Berkeley, Barratt Developments, Persimmon and Taylor Wimpey the top four performing stocks on the FTSE 100 as the prospect of a second referendum became more real.

UK P May's the government was defeated on two contempt of Parliament motions for not publishing the full legal advice on the withdrawal agreement. Backbenchers approved an amendment which gives them a greater say if the Brexit proposal is defeated in next week's meaningful vote.

Should parliament not support any deal before the Article 50 window expires, the chances of leaving without a deal are greatly reduced. It also raises the prospect of the UK not leaving at all should the public vote against it this time around in a second referendum. JPMorgan upped its odds on the possibility of Britain remaining in the EU to 40% from 20% and said it now sees the chances of a no-deal Brexit at 10%, reduced from 20%, and an orderly Brexit at 50% now versus 60% before. Comments from pro-Brexit International Trade Secretary Liam Fox also provided a boost, as he told a parliamentary committee that no Brexit was now a possibility.

As for the performers, Berkeley Group Holdings (The) (BKG) 3,485.00p 7.89%. Barratt Developments (BDEV) 479.90p 6.46% and Persimmon (PSN) 1,978.46p 6.14%. The non-performers were Ashtead Group (AHT) 1,683.50p -5.21%. Reckitt Benckiser Group (RB.) 6,401.00p -3.32%. Hargreaves Lansdown (HL.) 1,914.00p -3.28%

*UK Services data shocker*

Activity in the UK's services sector for November was reported to have softened to its weakest level for more than two years in November. Confidence levels also slumped due to Brexit angst. IHS Markit/CIPS UK services purchasing managers' index dropped from October's reading of 52.2 to 50.4, the lowest since July 2016. A reading below 50 indicates a contraction - A number of services sector companies said Brexit had prompted clients to delay investment decision, and there had been a slowdown in new business growth. There has now been a slowdown in new business growth for three consecutive months. Confidence for the year ahead showed the weakest degree of positive sentiment since July 2016.

*Technical levels*

*FTSE:*

The FTSE is negative on the charts with long bodied candlesticks that point to further downside as the bears remain in control will little in the way coming in from the bulls at this stage of the week, so far. The price is testing the barrier s of the daily Bollinger bands and the prior November lows, which could bring in some support. However, daily RSI has room to go until overbought conditions might encourage a buy-in or paring of shorts on profit taking and the next target is the S1 pivot point located at 6888. A break there opens YTD lows of 6850 and then S2 at 6820 and S3 at 6715. On the flipside, the pivot point is located at 6993 and above the daily high of 6977. 7016 was a prior low with the confluence of the 50-4hr SMA which guards the 21-4hr SMA at 7022. R1 is located at 7061 and the 2018 range 23.6% level is located at 7100. The 38.2% Fibo of 2018's range at 7262 is the primary objective thereafter. 

*DAX:*

We have a bearish bias on the charts still with the index consolidating below the gap after yesterday's drop. The index is in the lower end of the Bollinger bands and below the descending 21-D SMA now located at 11344. A break of the recent lows of 11141 leaves scope for a run to the 11007 level as the 19th Nov low. 10860 comes as the 2016 Aug-Nov level as the critical downside target.  Bulls need to get back above the 50-D SMA at 11559 ahead of the 23.6% Fibo target at 11617. Reported by FXstreet.com 1 hour ago.

*BIC Group - Press Release*
*Clichy - 5 December 2018*
Follow BIC latest news on * ** ** **               *

*Change in capital *

*Change in capital*

During its meeting held on 05 December 2018, the Board of Directors of SOCIETE BIC decided, as authorized by the Shareholders, to proceed to:

· a capital increase through the issuance of 59,921 new shares following exercise of share subscription options from 1^st of December 2017 to 31 October 2018,
· a capital decrease through cancellation of 687,396 shares.

Upon completion of these transactions, the share capital of SOCIETE BIC amounts to 175,675,638.34 euros divided into 45,988,387 shares of 3.82 euros each, fully paid-up.

*Contacts*

*Investor Relations**: *+33 1 45 19 52 00 *Press** Contacts*
Sophie Palliez-Capian
sophie.palliez@bicworld.com Albane de La Tour d'Artaise Albane.DeLaTourD'Artaise@bicworld.com
Michèle Ventura
michele.ventura@bicworld.com Isabelle de Segonzac: +33 1 53 70 74 70
isegonzac@image7.fr

For more information, please consult the corporate website: www.bicworld.com

*2019 Agenda (all dates to be confirmed)*

Full Year 2018 results 13 February 2019 Meeting - BIC Headquarters
First Quarter 2019 results 25 April 2019 Conference call
2019 AGM 22 May 2019 Meeting - BIC Headquarters

*About BIC*

BIC is a world leader in stationery, lighters and shavers. For more than 70 years, BIC has honored the tradition of providing high-quality, affordable products to consumers everywhere. Through this unwavering dedication BIC has become one of the most recognized brands and is a trademark registered worldwide for identifying BIC products which are sold in more than 160 countries around the world. In 2017, BIC Net Sales were 2,041.4 million euros. The Company is listed on "Euronext Paris" and is part of the SBF120 and CAC Mid 60 indexes. BIC is also part of the following Socially Responsible Investment indexes: CDP's "Leadership Level" (A-) and "Leadership Level" for the additional "Supplier" module, Euronext Vigeo - Eurozone 120, Euronext Vigeo - Europe 120, FTSE4Good indexes, Ethibel Pioneer and Ethibel Excellence Investment Registers, Ethibel Sustainability Index (ESI) Excellence Europe, Stoxx Global ESG Leaders Index.

*Attachment*

· BIC_capital change.pdf Reported by GlobeNewswire 56 minutes ago.

BARCELONA and Bayern Munich are both among the clubs with the cheapest season tickets in Europe. Reported by Daily Star 1 hour ago.

Police arrested dozens of suspected mobsters in Europe and South America on Wednesday in a huge international swoop targeting Italy's notorious 'Ndrangheta mafia clan, officials said. Reported by France 24 42 minutes ago.

· Improved lead production and additional time required to optimize production: anticipated non-fulfillment of the provisional financial target for the Group's German perimeter set for December 31^st 2018 due to current production levels and to 2018 backlog
· New discussions with financial partners to adapt and enlarge the framework of the German sub-group financing to its current cash flow generation and forecasted working capital requirements
· Cash situation closely monitored and remaining € 4 M from existing financing recently drawn
· Launch of a 24-month modernization project for the German group's organization and internal processes, aiming at succeeding in turning around sustainably

 

*Suresnes, December 5^th 2018: *Recylex S.A. (Euronext Paris: FR0000120388 - RX) announces today having started new discussions with all concerned financial partners in order to adapt the framework of the financing obtained by its German perimeter in December 2016 (and amended in September 2018) to its current and forecasted cash flow generation.
Since the second quarter of 2018, the Group's main lead furnace (BSF) production has experienced an important slow down^1 due to the technical adaptations required for its connection to the new reduction furnace. Improvements have been achieved which resulted in higher lead production in November but the current levels are still sustainably lower than forecasted in December 2016 when the financing was granted. Current financing commitments are no more adapted to the financial performance of the Group's German perimeter. In this context, the Group anticipates its German perimeter will not be able to reach its forecasted financial target at December 31^st 2018. Therefore, the financing framework of the German sub-group must be deeply reviewed.
Recylex S.A. will keep its investors informed of the development and the outcome of the ongoing discussions.

*Sebastian Rudow, Chairman and Chief Executive Officer of Recylex S.A., commented: *

"Whilst the new reduction furnace has started its operations, the main furnace production has been severely impacted for several months by its technical modifications. Teams are particularly committed to fix this situation and improvements are real but come at a slow pace. We are all doing our best efforts and working on sustainable solutions. However, we must also act responsibly and face this change in our horizon. Our lead segment business model is functioning and would be sustainable with an adapted financing: the current one is not anymore in line with the German perimeter's cash flows which are still lower than forecasted in 2016. In this context, we have started to renegotiate current financing with the target to reach arrangements that will give us the frame to focus not only on improvements of lead production, but also on management and organization. We all at Recylex are committed to this key challenge, in the interest of our employees, our shareholders and our business partners. I am dedicated in this context to develop adapted solutions to enable the Group to face its challenges. In addition, the Group has to modernize its organization and internal processes to succeed in turning around sustainably, we are therefore entering a 24-month internal project in this perspective."

1. *Update on the lead production situation*

Since the commissioning of the new lead reduction furnace in June 2018, the Group's lead production has experienced an important slow down^1 and has not yet recovered a satisfactory level. Indeed, since the second quarter of 2018, the availability rate of the main furnace (BSF) has been strongly impacted by the technical adaptations required for its connection to the new reduction furnace. Notably, the operation mode of the main BSF furnace has been modified from "continuous mode" to "batch mode" to be connected with the individual operation mode process of the reduction furnace. This change generated important technical difficulties which had not been fully forecasted during the preparation of the reduction furnace project and its construction phase.

During the last months, further modifications have been made to the BSF furnace to mend this situation both on the industrial equipment (such as the revision of certain pieces sizing or the change in certain processes) and also on the input mix of materials and its preparation. Moreover, due to the change of process of the smelter, the teams of Weser-Metall GmbH have been reinforced by experts and assisted by independent specialists. In the meantime, local management has been changed notably in the aim of giving teams the means to be more focused on their operations.
In parallel, with the reduction furnace production phase being successfully started as scheduled, the Group is gaining experience on managing this new equipment with its innovative technology.

Improvement works and measures are being currently pursued and teams continue their efforts with improvements being recorded since September 2018. More adjustments are planned which will require more time.
The current production of the two furnaces has been raised from 8,245 tonnes in September 2018 to 9,600 tonnes in October 2018 and 11,500 tonnes in November 2018. The next objective is to increase production above 12,000 tonnes per month and above 13,000 tonnes per month on a long term perspective.
Yet, the current production levels and the backlog accumulated in 2018 impact the Group's German perimeter's financial situation and consequently the Group's.

1. *Information on the Group's financial situation*

In this context, the Group anticipates that its German perimeter will not be able to reach its financial targets at December 31^st 2018, as defined in the financing signed in December 2016 and revised in September 2018^2. Target at December 31^st 2018 applicable to the Recylex's German sub-group was a cumulative EBITDA^3 for the rolling 12-month period, of at least € - 8.1 million (loss) whilst the German sub-group anticipates to reach € -10.1 million.
Considering the lenders rights under the existing financing agreement, in the event of non-compliance with any financial targets, the lenders could in theory suspend their financing and request immediate repayment of the amounts borrowed, which totaled € 59.6 million, as of October 31^st 2018. Moreover, this situation could generate the activation of the trusteeship arrangement put in place as a condition to the granting of the loan agreement to the German subsidiaries signed on December 29^th 2016^4, which would lead to the deconsolidation of the Group's German perimeter with the Trustees being able to exercise full shareholders' rights of the Group's companies Recylex GmbH, Weser-Metall GmbH and Harz-Metall GmbH. Finally, this breach of fulfilment of obligations by the German companies of their obligations under said loan agreement, would constitute an event of default within the framework of the € 16 million loan^4 contracted by Recylex S.A. with Glencore International AG. In this case, the lender could request the immediate repayment of the fully drawn amount^5.

Although the Group needs more time to solve its current industrial issues in order to optimize its lead production levels, from a metallurgical perspective, Weser-Metall GmbH smelter's process, with its two furnaces, is operational. Its business model would be sustainable in the future with a financing framework in line with its current and forecasted cash flow generation.
In this context, the Group has started new discussions with all its financial partners in order to adapt and enlarge the financing framework (granted in December 2016 and amended in September 2018), to its German perimeter's financial performance.

As already disclosed in its previous press releases, measures have been taken to adjust the Group's working capital requirements to the lower lead production. As a reminder, Weser-Metall GmbH being currently Recylex S.A.'s sole client, its cash flow is highly dependent on that of Weser-Metall GmbH. In this context, the Group's cash situation is tight and is being closely monitored.
As a reminder, in accordance with the conditions for the granting of the 2016 financing, Glencore International AG gave commitments to the Group's German subsidiaries to cover notably their specific cash requirements (up to maximum € 25 million). Given the forecasted need of cash by the end of December 2018, the Group's German perimeter has drawn the remaining € 4 million on this available financing commitment^4 which is now fully used.

In this context, the consolidated net debt^6 amounted to € 101.4 million as of October 31^st 2018 compared to € 101.2 million at June 30^th 2018 and the Group's net cash position^7 stood at € -7.1 million as of November 30^th 2018 compared to € - 8.8 million as at June 30^th 2018.

1. *24-month modernization project for German group organization and internal processes*

Considering the context described above and willing to anticipate the challenges ahead, the Group has launched a 24-month modernization project for management organization and internal processes in Germany, aiming at succeeding in turning around sustainably.
The objective is to bring the Group to more modern operations notably in terms of industrial, management and administration efficiencies.

In order to develop more synergies between the Group's companies, all departments and processes have started to be reinforced.

1. *Pursuance of the L'Estaque site rehabilitation*

Recylex S.A. is pursuing the rehabilitation works of its inactive L'Estaque site in Marseille. Remaining works amount to € 8.3 million as of June 30^th 2018 (compared to € 9.9 million as of December 31^st 2017).

Recylex S.A. does not anticipate any potential future sale of this site before its rehabilitation works are completely finalized.

1. *Information of Weser-Metall GmbH regarding potential misbehaviour of a Nigerian lead acid battery treatment plant*

Weser-Metall GmbH has become recently aware of potential misbehaviour, regarding Health, Safety & Environment, of some Nigerian companies.

Weser-Metall GmbH has only identified one of its suppliers based in the U.K which has sourced lead secondary materials from one of the Nigerian concerned companies. Weser-Metall GmbH had no direct commercial purchases from this Nigerian company and has not been informed by its supplier of any legal infringement or misbehaviour by this company. All deliveries of concerned secondary materials to Weser-Metall GmbH were validated by the environmental authorities.
Weser-Metall GmbH decided to stop all deliveries of secondary materials from this source and is carrying out further analysis.

Weser-Metall GmbH produces lead ingots in an environmental sound manner and is certified with ISO 14001, ISO 9001, and ISO 50001 and as a waste management company (Entsorgungsfachbetrieb).
Weser-Metall GmbH as such contributes to worldwide circular economy in accordance with European standards and the most advanced recycling expertise.

***************************************
*Regenerating the urban mines*
*With operations in France and Germany, Recylex is a European group specialized in lead, plastics and zinc recycling, as well as a producer of special metals. A key player in the circular economy with long-standing expertise in urban waste recovery, the Group has more than 660 employees in Europe and generated consolidated sales of € 450 million in 2017. For more information about Recylex Group: *www.recylex.fr*, on Linkedin and twitter: **@Recylex*

***************************************

*Press/Investor contact:*
*Gabriel ZEITLIN*
+ 33 (0)1 58 47 29 89
gabriel.zeitlin@recylex.fr

^1 See press releases dated July 26^th 2018, September 28^th 2018 and 30^th October 2018.
^2 See press release dated September 24^th 2018 and note 10 to the condensed interim financial statements at June 30^th 2018.
^3 Operating income plus depreciation of property, plant and equipment, and amortization of intangible and financial assets and of goodwill.
^4 See notes 30 and 32 to the 2017 financial consolidated statements.
^5 See note 10 to the condensed interim financial statements at June 30^th 2018 as well as notes 30 and 32 to the 2017 consolidated financial statements.
^6Excluding contingent liabilities - See note 1.F to the condensed interim financial statements at June 30^th 2018.
^7 Cash net of bank overdraft facilities and credit lines used.

*Attachment*

· To view the PDF file, click here.pdf Reported by GlobeNewswire 36 minutes ago.

HMD Global just announced the Nokia 8.1, a successor to the midrange Nokia 7 Plus that was released earlier this year. The new handset, which is set to launch in the UK and Europe next year on January 14th for £379.99 (€399), swaps out the 7 Plus’ Snapdragon 660 for a Snapdragon 710, and it includes a notch and HDR10 support for its 2160 x 1440 resolution display.

Otherwise, the specs are more or less in line with what you’d expect from this price point, with 4GB of RAM flanked by 64GB of internal storage (expandable by up to 400GB via microSD). Its 3,500mAh battery can be fast charged at 18W, and yes, it has a headphone jack if you don’t want to make the jump to wireless. (But if you do, then you’ll get Bluetooth AptX support for good... Reported by The Verge 37 minutes ago.

Three Rivers, Michigan, Dec. 05, 2018 (GLOBE NEWSWIRE) --

Armstrong International has launched SAGE UMT™ – a wireless, hand-held steam trap testing solution that enables accurate, on-the-go testing of steam trap performance. SAGE UMT™ leverages radio-frequency identification (RFID) technology to quickly locate and identify steam traps. Its piezoelectric acoustic and non-contact infrared temperature sensor delivers accurate and precise detection to identify steam traps that are performing in good, cold, blow-through and leaking conditions.

“SAGE UMT™ puts state-of-the-art technology in the hands of technicians to eliminate guesswork and significantly reduce the time it takes to survey, test and record steam trap performance,” said Kurt Armstrong, Chief Information Officer of Armstrong International.

SAGE UMT™ integrates with the Armstrong SAGE^® Smart Thermal Utility System Management platform and syncs wirelessly via Bluetooth to the SAGE^® Mobile app to deliver real-time diagnostics and eliminate manual entry associated with offline steam trap survey data collection. Data can be instantly uploaded to the cloud by SAGE^® for secure storage and on-going steam trap analysis to support system-wide utility management.

SAGE UMT™ is rugged, water resistant and designed with ergonomic features including an easy-to-hold handle with a rubberized ribbed grip. It’s comfortable to carry and easy to operate for both right-hand and left-hand users. It comes with a convenient holster that keeps the unit secure and protected. SAGE UMT™ can operate for 10 hours or more without recharging. Watch this video to see SAGE UMT™ in action and contact your Armstrong representative to order.

About Armstrong International
Armstrong International provides intelligent system solutions that improve utility performance, lower energy consumption, and reduce environmental emissions, while providing an enjoyable experience. Founded in 1900, Armstrong International is a family-owned company headquartered in the United States, with manufacturing, sales and seminar centers located throughout The Americas, Asia, and Europe/Middle East/Africa. More information can be found at www.armstronginternational.com.

*Attachment*

· Armstrong SAGE UMT™

CONTACT: Contact:Jeff Nowicki, Armstrong International
Phone: (269) 279-3324
E-mail: jnowicki@armstronginternational.com Reported by GlobeNewswire 17 minutes ago.